Cleve A, Fritzemeier K-H, Haendler B, Heinrich N, Möller C, Schwede W, Wintermantel T
Bayer Pharma AG, Muellerstr. 178, Berlin, Germany.
Handb Exp Pharmacol. 2012(214):543-87. doi: 10.1007/978-3-642-30726-3_24.
Sex steroid receptors are ligand-triggered transcription factors. Oestrogen, progesterone and androgen receptors form, together with the glucocorticoid and mineralocorticoid receptors, a subgroup of the superfamily of nuclear receptors. They share a common mode of action, namely translating a hormone-i.e. a small-molecule signal-from outside to changes in gene expression and cell fate, and thereby represent "natural" pharmacological targets.For pharmacological therapy, these receptors have originally been addressed by hormones and synthetic hormone analogues in order to overcome pathologies related to deficiencies in the natural ligands. Another major use for female sex hormone receptor modulators is oral contraception, i.e. birth control.On the other side, blocking the activity of sex steroid receptors has become an established way to treat hormone-dependent malignancies, such as breast and prostate cancer.In this review, we will discuss how the experience gained from the classical pharmacology of these receptors and their molecular similarities led to new options for the treatment of gender-specific diseases and highlight recent progress in medicinal chemistry of sex hormone-modulating drugs.
性类固醇受体是配体触发的转录因子。雌激素、孕激素和雄激素受体与糖皮质激素和盐皮质激素受体一起,构成核受体超家族的一个亚组。它们具有共同的作用模式,即将来自外部的激素(即小分子信号)转化为基因表达和细胞命运的变化,因此代表了“天然”的药理学靶点。在药物治疗中,这些受体最初是通过激素和合成激素类似物来作用的,以克服与天然配体缺乏相关的病理状况。女性性激素受体调节剂的另一个主要用途是口服避孕,即节育。另一方面,阻断性类固醇受体的活性已成为治疗激素依赖性恶性肿瘤(如乳腺癌和前列腺癌)的既定方法。在本综述中,我们将讨论从这些受体的经典药理学中获得的经验以及它们的分子相似性如何为治疗性别特异性疾病带来新的选择,并强调性激素调节药物药物化学的最新进展。